Wedbush analyst David Nierengarten has reaffirmed an Outperform rating for Perspective Therapeutics, Inc. (CATX) with a 12-month price target of $11, following the presentation of updated interim data from its lead clinical program, VMT-a-NET, at the AACR Annual Meeting. This precision-targeted alpha therapy is currently in a phase 1/2a trial for patients with unresectable or metastatic neuroendocrine tumors (NETs), and the latest data shows promising results from 64 treated patients, bolstering its clinical profile.
The significance of this update lies in its potential to enhance investor confidence in CATX, especially as the company is on track to provide initial efficacy data later this year. With the competitive landscape shifting—particularly following SNY’s deprioritization of AlphaMedix—VMT-a-NET is positioned as a frontrunner in the targeted alpha therapy space.
Market professionals should consider CATX shares as a strategic buy ahead of anticipated data and regulatory developments in 2026, which could catalyze further stock appreciation.
Source: nasdaq.com